These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30708392)

  • 1. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
    DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
    Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
    Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
    Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
    Berhie SH; Riley LE; Bryant AS
    Am J Perinatol; 2019 Aug; 36(10):1066-1071. PubMed ID: 30508869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.
    Turitz AL; Bastek JA; Purisch SE; Elovitz MA; Levine LD
    Am J Obstet Gynecol; 2016 Apr; 214(4):536.e1-536.e5. PubMed ID: 26519784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy after periviable birth: making the case for innovative delivery of interpregnancy care.
    Vani K; Facco FL; Himes KP
    J Matern Fetal Neonatal Med; 2019 Nov; 32(21):3577-3580. PubMed ID: 29681199
    [No Abstract]   [Full Text] [Related]  

  • 9. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
    Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org
    Am J Obstet Gynecol; 2020 Jul; 223(1):B16-B18. PubMed ID: 32277894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.